Title:
USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
Document Type and Number:
Japanese Patent JP2018024686
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide methods for treating hematological malignancy such as B cell malignancy, leukemia, lymphoproliferative disorder, myeloid disorder, or non Hodgkin's lymphoma in an individual.SOLUTION: A method of the invention uses: a. (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (i.e., PCI-32765/ibrutinib) or pharmaceutically acceptable salt thereof; and b. obinutuzumab (GA101) or pharmaceutically acceptable salt thereof. The ibrutinib may be administered at a dose of 300-1000 mg/day, preferably 420-840 mg/day. The ibrutinib and obinutuzumab may be used in a single dosage form or in a combination of individual dosage forms.SELECTED DRAWING: None
Inventors:
JOSEPH J BUGGY
ELIAS LAURENCE
GWEN FYFE
ERIC HEDRICK
DAVID J LOURY
TARAK D MODY
ELIAS LAURENCE
GWEN FYFE
ERIC HEDRICK
DAVID J LOURY
TARAK D MODY
Application Number:
JP2017174407A
Publication Date:
February 15, 2018
Filing Date:
September 11, 2017
Export Citation:
Assignee:
PHARMACYLICS LLC
International Classes:
A61K45/00; A61K31/337; A61K31/454; A61K31/475; A61K31/519; A61K31/52; A61K31/5383; A61K31/539; A61K31/573; A61K31/69; A61K31/704; A61K31/7068; A61K31/7076; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| JP2014530877A | 2014-11-20 | |||
| JP6506555B2 | 2019-04-24 |
Foreign References:
| US20110184001A1 | 2011-07-28 | |||
| WO2010065824A2 | 2010-06-10 | |||
| WO2011068560A1 | 2011-06-09 |
Other References:
BLOOD, vol. 115, no. 22, JPN6017016298, 2010, pages 4393 - 4402, ISSN: 0003951980
BLOOD, vol. 118, no. 19, JPN6017016294, 2011, pages 5178 - 5188, ISSN: 0003951981
BLOOD, vol. 118, no. 19, JPN6017016294, 2011, pages 5178 - 5188, ISSN: 0003951981
Attorney, Agent or Firm:
Kazuhiro Kiyohara